EyePoint Pharmaceuticals Files 8-K
Ticker: EYPT · Form: 8-K · Filed: Mar 4, 2024 · CIK: 1314102
| Field | Detail |
|---|---|
| Company | Eyepoint Pharmaceuticals, Inc. (EYPT) |
| Form Type | 8-K |
| Filed Date | Mar 4, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, corporate-update
Related Tickers: EYPT
TL;DR
EYPT filed an 8-K on 3/4/24. Standard disclosure.
AI Summary
EyePoint Pharmaceuticals, Inc. filed an 8-K on March 4, 2024, reporting other events and financial statements. The company, formerly known as pSivida Corp. and pSivida LTD, is incorporated in Delaware and headquartered in Watertown, Massachusetts.
Why It Matters
This filing indicates a routine update or disclosure from EyePoint Pharmaceuticals, Inc. to the SEC, which may contain important information for investors.
Risk Assessment
Risk Level: low — This is a standard 8-K filing for reporting events and financial statements, not indicating any immediate material changes or risks.
Key Numbers
- 000-51122 — SEC File Number (Identifies the company's filing with the SEC.)
- 26-2774444 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- EyePoint Pharmaceuticals, Inc. (company) — Registrant
- pSivida Corp. (company) — Former company name
- pSivida LTD (company) — Former company name
- March 04, 2024 (date) — Date of report
- Watertown, Massachusetts (location) — Principal executive offices
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The provided text does not detail the specific 'Other Events' reported, only that this item is included in the filing.
What is the significance of the former company names 'pSivida Corp.' and 'pSivida LTD'?
These are former names of EyePoint Pharmaceuticals, Inc., indicating a history of corporate name changes.
When did EyePoint Pharmaceuticals, Inc. change its name from pSivida Corp.?
The filing indicates the name change from pSivida Corp. occurred on June 19, 2008.
What is the business address of EyePoint Pharmaceuticals, Inc.?
The principal executive offices are located at 480 Pleasant Street, Suite B300, Watertown, Massachusetts, 02472.
What is the SIC code for EyePoint Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code is 3826, for LABORATORY ANALYTICAL INSTRUMENTS.
Filing Stats: 468 words · 2 min read · ~2 pages · Grade level 9.5 · Accepted 2024-03-04 07:01:44
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 EYPT The Nasdaq Global Market Ind
Filing Documents
- eypt-20240304.htm (8-K) — 40KB
- eypt-ex99_1.htm (EX-99.1) — 23KB
- img96707757_0.jpg (GRAPHIC) — 5KB
- 0000950170-24-024346.txt ( ) — 208KB
- eypt-20240304.xsd (EX-101.SCH) — 40KB
- eypt-20240304_htm.xml (XML) — 5KB
01. Other Events
Item 8.01. Other Events. On March 4, 2024, EyePoint Pharmaceuticals, Inc. (the "Company") issued a press release announcing the appointment of Ramiro Ribeiro, M.D., Ph.D., as the Company's Chief Medical Officer, effective as of March 1, 2024, succeeding Dario Paggiarino, M.D., who had served as EyePoint's Chief Medical Officer since 2016 and will be leaving the company effective March 31, 2024. A copy of the press release, which is filed with this Current Report on Form 8-K as Exhibit 99.1, is hereby filed pursuant to this Item 8.01.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of EyePoint Pharmaceuticals, Inc., dated March 4, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EYEPOINT PHARMACEUTICALS, INC. Date: March 4, 2024 By: /s/ George O. Elston George O. Elston Executive Vice President and Chief Financial Officer